Attached files
file | filename |
---|---|
EX-99.1 - LETTER FROM CAMILLE D. SAMUELS DATED JANUARY 21, 2011 - Paratek Pharmaceuticals, Inc. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
January 24, 2011 (January 21, 2011)
Date of Report (date of earliest event reported)
TRANSCEPT PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware | 000-51967 | 33-0960223 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
1003 W. Cutting Blvd., Suite #110
Point Richmond, California 94804
(Address of principal executive offices)
(510) 215-3500
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As of January 21, 2011, Camille D. Samuels, a member of the board of directors of Transcept Pharmaceuticals, Inc. (the Company), and a member of its Compensation Committee, notified the Company that she will resign at the Companys 2011 Annual Meeting of Stockholders, which is currently scheduled for June 23, 2011. Ms. Samuels decision was not a result of any disagreement with the Company.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
Description | |
99.1 | Letter from Camille D. Samuels dated January 21, 2011 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRANSCEPT PHARMACEUTICALS, INC. | ||||
Date: January 24, 2011 | ||||
By: | /s/ Marilyn E. Wortzman | |||
Name: Marilyn E. Wortzman | ||||
Title: Vice President, Finance |
EXHIBIT INDEX
Exhibit No. |
Description | |
99.1 | Letter from Camille D. Samuels dated January 21, 2011 |